Welcome To ChemAnalyst
The US cefpodoxime proxetil market witnesses a consistent positive movement throughout December **** with prices further rising by around *.*** as the year **** ends. This trend has continued from the positive movement that has been identified in the latter half of ****. There have been reports from participants across significant regions for the pharmaceutical market that prices for cefpodoxime proxetil have continued to rise. Being one of the most prescribed third-generation oral cephalosporins with wide uses in respiratory, urinary, and some other bacterial infections, cefpodoxime proxetil is an indispensable drug in the world antibiotics list. Therefore, its market is especially responsive to changes in its availability. On the supply side, December **** was marked by a low cefpodoxime proxetil availability of active pharmaceutical ingredients (APIs) due to continuing pressure from higher raw material prices, energy prices, and regulatory compliance in the main producing areas.
We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site or by closing this box, you consent to our use of cookies. More info.

Leave a Comment
Comments (0)